It seems ineptness or negligence on the part of the CHMP to assign two non-expert rapporteurs to review and judge the results of a CNS therapeutic. If I were Missling, I would voice strong concerns over such sloppiness.
Perhaps it was done on purpose in order to delay the approval by applying an improper and disingenuous review by non-experts. Can't give Anavex an easier pathway than Lilly.
Missling should make a strong request for more expert CNS related rapporteurs.
Market Data 
Markets 
AI
